QARADAKHI, T., L. K. GADANEC, K. R. MCSWEENEY, A. TACEY, V. APOSTOLOPOULOS, I. LEVINGER, K. RIMAROVA, E. E. EGOM, L. RODRIGO, Peter KRUŽLIAK, P. KUBATKA a A. ZULLI. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clinical and Experimental Pharmacology and Physiology. Australia: Blackwell Publishing Australia, 2020, roč. 47, č. 5, s. 751-758. ISSN 0305-1870. Dostupné z: https://dx.doi.org/10.1111/1440-1681.13251.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases
Autoři QARADAKHI, T. (36 Austrálie), L. K. GADANEC (36 Austrálie), K. R. MCSWEENEY (36 Austrálie), A. TACEY (36 Austrálie), V. APOSTOLOPOULOS (36 Austrálie), I. LEVINGER (36 Austrálie), K. RIMAROVA (703 Slovensko), E. E. EGOM (124 Kanada), L. RODRIGO (724 Španělsko), Peter KRUŽLIAK (703 Slovensko, garant, domácí), P. KUBATKA (703 Slovensko) a A. ZULLI (36 Austrálie).
Vydání Clinical and Experimental Pharmacology and Physiology, Australia, Blackwell Publishing Australia, 2020, 0305-1870.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30105 Physiology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.557
Kód RIV RIV/00216224:14110/20:00115986
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1111/1440-1681.13251
UT WoS 000509618900001
Klíčová slova anglicky angiotensin-converting enzyme II; cardiovascular disease; diminazene aceturate; endothelial dysfunction; renin angiotensin system
Štítky 14110121, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 15. 7. 2020 10:04.
Anotace
The renin angiotensin system (RAS) regulates fluid balance, blood pressure and maintains vascular tone. The potent vasoconstrictor angiotensin II (Ang II) produced by angiotensin-converting enzyme (ACE) comprises the classical RAS. The non-classical RAS involves the conversion of Ang II via ACE2 into the vasodilator Ang (1-7) to counterbalance the effects of Ang II. Furthermore, ACE2 converts AngA into another vasodilator named alamandine. The over activation of the classical RAS (increased vasoconstriction) and depletion of the non-classical RAS (decreased vasodilation) results in vascular dysfunction. Vascular dysfunction is the leading cause of atherosclerosis and cardiovascular disease (CVD). Additionally, local RAS is expressed in various tissues and regulates cellular functions. RAS dysregulation is involved in other several diseases such as inflammation, renal dysfunction and even cancer growth. An approach in restoring vascular dysfunction and other pathological diseases is to either increase the activity of ACE2 or reduce the effect of the classical RAS by counterbalancing Ang II effects. The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2. DIZE has been shown to exert beneficial effects in CVD experimental models of hypertension, myocardial infarction, type 1 diabetes and atherosclerosis. Thus, this review focuses on DIZE and its effect in several tissues such as blood vessels, cardiac, renal, immune and cancer cells.
VytisknoutZobrazeno: 10. 9. 2024 09:19